Assessment of Cardiotoxicity by Cardiac MRI Versus MUGA Scans in Breast Cancer Patients Receiving Trastuzumab: A Double-Blinded Prospective Observational Pilot Study
Herceptin has shown significant improvement in breast cancer therapy and improved survival
of patients over-expressing the HER-2 protein by 50%. However, Herceptin has shown to
negatively affect the heart, and frequent heart monitoring with multiple gated acquisition
(MUGA) scans is required. MUGA scans use radiation and are not very accurate. This study
will use cardiac magnetic resonance images (CMRs) to evaluate heart function and compare to
MUGA scans in patients receiving Herceptin for early-stage breast cancer. In addition, novel
biomarkers will also be assessed at the same time to help identify possible patients at risk
for developing heart toxicities.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society